Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Effect of bromhexine in hospitalized patients with COVID-19.
Tolouian R, Mulla ZD, Jamaati H, Babamahmoodi A, Marjani M, Eskandari R, Dastan F. Tolouian R, et al. J Investig Med. 2023 Oct;71(7):691-699. doi: 10.1136/jim-2020-001747. J Investig Med. 2023. PMID: 33722999 Clinical Trial.
BACKGROUND: Bromhexine is a potent inhibitor of transmembrane serine protease 2 and appears to have an antiviral effect in controlling influenza and parainfluenza infection; however, its efficacy in COVID-19 is controversial. METHODS: A group of hospitalized …
BACKGROUND: Bromhexine is a potent inhibitor of transmembrane serine protease 2 and appears to have an antiviral effect in controllin …
Evaluation of the efficacy of N-acetylcysteine and bromhexine compared with standard care in preventing hospitalization of outpatients with COVID-19: a double blind randomized clinical trial.
Eslami Ghayour A, Nazari S, Keramat F, Shahbazi F, Eslami-Ghayour A. Eslami Ghayour A, et al. Rev Clin Esp (Barc). 2024 Feb;224(2):86-95. doi: 10.1016/j.rceng.2023.12.011. Epub 2024 Jan 11. Rev Clin Esp (Barc). 2024. PMID: 38215974 Clinical Trial.
In this study, we included patients who tested positive for COVID-19- PCR and were symptomatic, excluding those who were pregnant or had received a COVID-19 vaccine. ...CONCLUSION: In conclusion, the results of this study indicate that NAC and bromh …
In this study, we included patients who tested positive for COVID-19- PCR and were symptomatic, excluding those who were pregn …
Bromhexine Hydrochloride Tablets for the Treatment of Moderate COVID-19: An Open-Label Randomized Controlled Pilot Study.
Li T, Sun L, Zhang W, Zheng C, Jiang C, Chen M, Chen D, Dai Z, Bao S, Shen X. Li T, et al. Clin Transl Sci. 2020 Nov;13(6):1096-1102. doi: 10.1111/cts.12881. Epub 2020 Oct 10. Clin Transl Sci. 2020. PMID: 32881359 Free PMC article. Clinical Trial.
This open-label randomized controlled pilot study aimed to test the study feasibility of bromhexine hydrochloride (BRH) tablets for the treatment of mild or moderate coronavirus disease 2019 (COVID-19) and to explore its clinical efficacy and safety. Patients …
This open-label randomized controlled pilot study aimed to test the study feasibility of bromhexine hydrochloride (BRH) tablets for t …
New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial).
Granados-Montiel J, Hazan-Lasri E, Franco-Cendejas R, Chávez-Heres T, Silva-Bermudez P, Aguilar-Gaytán R, Manzano-León N, Méndez-Maldonado K, Alvarez-Arce A, Martínez-Portilla RJ. Granados-Montiel J, et al. BMJ Open. 2021 Aug 3;11(8):e045190. doi: 10.1136/bmjopen-2020-045190. BMJ Open. 2021. PMID: 34344672 Free PMC article. Clinical Trial.
High infectivity of SARS-CoV-2 is related with cell entry mechanism, through the ACE receptor. ...We propose studying prophylactic treatment with hydroxychloroquine (HCQ) and bromhexine (BHH), which have been shown to be effective in preventing SARS …
High infectivity of SARS-CoV-2 is related with cell entry mechanism, through the ACE receptor. ...We propose studying p …
Interventions for treatment of COVID-19: Second edition of a living systematic review with meta-analyses and trial sequential analyses (The LIVING Project).
Juul S, Nielsen EE, Feinberg J, Siddiqui F, Jørgensen CK, Barot E, Holgersson J, Nielsen N, Bentzer P, Veroniki AA, Thabane L, Bu F, Klingenberg S, Gluud C, Jakobsen JC. Juul S, et al. PLoS One. 2021 Mar 11;16(3):e0248132. doi: 10.1371/journal.pone.0248132. eCollection 2021. PLoS One. 2021. PMID: 33705495 Free PMC article.
BACKGROUND: COVID-19 is a rapidly spreading disease that has caused extensive burden to individuals, families, countries, and the world. Effective treatments of COVID-19 are urgently needed. This is the second edition of a living systematic review of r …
BACKGROUND: COVID-19 is a rapidly spreading disease that has caused extensive burden to individuals, families, countries, and …